83863-72-3

Basic information

• Product Name: N-Carbethoxy-3-methoxy-4-piperidone
• Synonyms: N-CARBETHOXY-3-METHOXY-4-PIPERIDONE;3-METHOXY-4-OXO-PIPERIDINE-1-CARBOXYLIC ACID ETHYL ESTER;ethyl 3-methoxy-4-oxopiperidine-1-carboxylate;N-Carbethoxy-3-methoxy-4-piperidine;N-Carboethoxy-3-Methoxy-4-Piperidone;1-CARBETHOXY-3-METHOXY-4-PIPERIDONE;3-Methoxy-4-oxo-1-piperidinecarboxylic acid ethyl ester;Einecs 281-138-0
• CAS NO: 83863-72-3
• Molecular Formula: C₉H₁₅NO₄
• Molecular Weight: 201.22
• EINECS: 281-138-0
• Mol File: 83863-72-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 301.3 °C at 760 mmHg
• Flash Point: 136 °C
• Appearance: /
• Density: 1.16 g/cm³
• Vapor Pressure: 0.00106mmHg at 25°C
• Refractive Index: 1.481
• Storage Temp.: 2-8°C
• CAS DataBase Reference: N-Carbethoxy-3-methoxy-4-piperidone(CAS DataBase Reference)
• NIST Chemistry Reference: N-Carbethoxy-3-methoxy-4-piperidone(83863-72-3)
• EPA Substance Registry System: N-Carbethoxy-3-methoxy-4-piperidone(83863-72-3)

Safety Data

• Hazardous Substances Data: 83863-72-3(Hazardous Substances Data)

Usage

General Description

N-Carbethoxy-3-methoxy-4-piperidone is a synthetic organic compound with the chemical formula C11H17NO4. It is a derivative of piperidone, which is commonly used as a precursor in the synthesis of pharmaceuticals and agrochemicals. The carbethoxy and methoxy groups attached to the piperidone ring are important functional groups that can undergo various chemical reactions for the modification and production of other compounds. N-Carbethoxy-3-methoxy-4-piperidone has potential applications in the pharmaceutical industry as a key intermediate for the synthesis of various drugs and pharmaceutical products. Its chemical structure and properties make it an important building block for the production of a wide range of organic compounds.

InChI:InChI=1/C9H15NO4/c1-3-14-9(12)10-5-4-7(11)8(6-10)13-2/h8H,3-6H2,1-2H3

Upstream product

• 83898-43-5 ethyl 3-hydroxy-4,4-dimethoxy-1-piperidinecarboxylate 
• 83863-73-4 (-)-ethyl 3,4,4-trimethoxy-1-piperidinecarboxylate 
• 29976-53-2 N-ethoxycarbonyl-4-piperidone 
• 67-56-1 methanol 
• 203984-87-6 4-Methoxy-3,6-dihydro-2H-pyridine-1-carboxylic acid ethyl ester 

Downstream Products

• 907543-85-5 ethyl (3R,4S)-4-(benzylamino)-3-methoxypiperidine-1-carboxylate 
• 907543-86-6 ethyl (3S,4R)-4-(benzylamino)-3-methoxypiperidine-1-carboxylate 
• 882737-71-5 ethyl (3S,4R)-4-amino-3-methoxypiperidine-1-carboxylate 
• 907572-18-3 ethyl (-)-cis-4-amino-3-methoxy-1-piperidinecarboxylate 
• 1000027-11-1 ethyl 4-(dibenzylamino)-3-methoxypiperidine-1-carboxylate 

Relevant articles and documents

LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES

Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein m, R1, R2, R3, R4, R5, R6, X1, X2, X3 and X4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with the 5-HT4 receptor.

Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099)

AZD5099 (compound 63) is an antibacterial agent that entered phase 1 clinical trials targeting infections caused by Gram-positive and fastidious Gram-negative bacteria. It was derived from previously reported pyrrolamide antibacterials and a fragment-based approach targeting the ATP binding site of bacterial type II topoisomerases. The program described herein varied a 3-piperidine substituent and incorporated 4-thiazole substituents that form a seven-membered ring intramolecular hydrogen bond with a 5-position carboxylic acid. Improved antibacterial activity and lower in vivo clearances were achieved. The lower clearances were attributed, in part, to reduced recognition by the multidrug resistant transporter Mrp2. Compound 63 showed notable efficacy in a mouse neutropenic Staphylococcus aureus infection model. Resistance frequency versus the drug was low, and reports of clinical resistance due to alteration of the target are few. Hence, 63 could offer a novel treatment for serious issues of resistance to currently used antibacterials.

Reaction of enol ethers with lead tetraacetate : An improved method for the synthesis of α- methoxy ketones

The reaction of cyclic enol ethers with lead tetraacetate in methanol in the presence of BF3.Et2O at 0°C gives α- methoxy cyclic ketones.